<?xml version="1.0" encoding="UTF-8"?><!-- Converted from Majour with majour2a++ V1.11 --><!--Automatically converted from version 2.3 to 2.4--><!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
   <PublisherInfo>
      <PublisherName>Springer-Verlag</PublisherName>
      <PublisherLocation>Berlin/Heidelberg</PublisherLocation>
   </PublisherInfo>
   <Journal>
      <JournalInfo JournalProductType="Legacy" NumberingStyle="Unnumbered">
         <JournalID>401</JournalID>
         <JournalPrintISSN>0001-6322</JournalPrintISSN>
         <JournalElectronicISSN>1432-0533</JournalElectronicISSN>
         <JournalSPIN/>
         <JournalTitle>Acta Neuropathologica</JournalTitle>
         <JournalSubTitle/>
         <JournalAbbreviatedTitle>Acta Neuropathol</JournalAbbreviatedTitle>
<JournalSubjectGroup>
<JournalSubject Type="Primary">Legacy</JournalSubject>
</JournalSubjectGroup>
      </JournalInfo>
      <Volume>
         <VolumeInfo VolumeType="Regular">
<VolumeIDStart>101</VolumeIDStart>
<VolumeIDEnd>101</VolumeIDEnd>
<VolumeIssueCount/>
</VolumeInfo>
         <Issue IssueType="Regular">
            <IssueInfo TocLevels="0">
               <IssueIDStart>4</IssueIDStart>
               <IssueIDEnd>4</IssueIDEnd>
               <IssueHistory>
                  <OnlineDate>
                     <Year>2001</Year>
                     <Month>3</Month>
                     <Day>29</Day>
                  </OnlineDate>
                  <PrintDate>
                     <Year>2001</Year>
                     <Month>4</Month>
                     <Day/>
                  </PrintDate>
                  <CoverDate>
                     <Year>2001</Year>
                     <Month>4</Month>
                  </CoverDate>
               </IssueHistory>
               <IssueCopyright>
                  <CopyrightHolderName>Springer-Verlag</CopyrightHolderName>
                  <CopyrightYear>2001</CopyrightYear>
               </IssueCopyright>
            </IssueInfo>
            <Article ID="Art1">
               <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
                  <ArticleID>00261</ArticleID>
                  <ArticleDOI>10.1007/s004010000261</ArticleDOI>
                  <ArticleTitle Language="En">High cyclin E/low p27<Superscript>Kip1</Superscript> expression is associated with poor prognosis in astrocytomas</ArticleTitle>
                  <ArticleCategory>Regular paper</ArticleCategory>
                  <ArticleFirstPage>334</ArticleFirstPage>
                  <ArticleLastPage>340</ArticleLastPage>
                  <ArticleHistory>
                     <Received>
                        <Year>1999</Year>
                        <Month>09</Month>
                        <Day>20</Day>
                     </Received>
                     <Revised>
                        <Year>2000</Year>
                        <Month>05</Month>
                        <Day>05</Day>
                     </Revised>
                     <Accepted>
                        <Year>2000</Year>
                        <Month>05</Month>
                        <Day>08</Day>
                     </Accepted>
                  </ArticleHistory>
                  <ArticleCopyright>
                     <CopyrightHolderName>Springer-Verlag</CopyrightHolderName>
                     <CopyrightYear>2001</CopyrightYear>
                  </ArticleCopyright>
<ArticleGrants>
<MetadataGrant Grant="OpenAccess"/>
<AbstractGrant Grant="OpenAccess"/>
<BodyPDFGrant Grant="Restricted"/>
<BodyHTMLGrant Grant="Restricted"/>
<BibliographyGrant Grant="Restricted"/>
<ESMGrant Grant="Restricted"/>
</ArticleGrants>
               </ArticleInfo>
               <ArticleHeader>
                  <AuthorGroup>
                     <Author AffiliationIDS="A1">
                        <AuthorName DisplayOrder="Western">
                           <GivenName>Takashi</GivenName>
                           <FamilyName>Tamiya</FamilyName>
                        </AuthorName>
                        <Contact>
                           <Phone>+81-86-2357336</Phone>
                           <Fax>+81-86-2270191</Fax>
                           <Email>ttamiya@med.okayama-u.ac.jp</Email>
                        </Contact>
                     </Author>
                     <Author AffiliationIDS="A1">
                        <AuthorName DisplayOrder="Western">
                           <GivenName>Shinichiro</GivenName>
                           <FamilyName>Mizumatsu</FamilyName>
                        </AuthorName>
                     </Author>
                     <Author AffiliationIDS="A1">
                        <AuthorName DisplayOrder="Western">
                           <GivenName>Yasuhiro</GivenName>
                           <FamilyName>Ono</FamilyName>
                        </AuthorName>
                     </Author>
                     <Author AffiliationIDS="A1">
                        <AuthorName DisplayOrder="Western">
                           <GivenName>Tomoyasu</GivenName>
                           <FamilyName>Abe</FamilyName>
                        </AuthorName>
                     </Author>
                     <Author AffiliationIDS="A1">
                        <AuthorName DisplayOrder="Western">
                           <GivenName>Kengo</GivenName>
                           <FamilyName>Matsumoto</FamilyName>
                        </AuthorName>
                     </Author>
                     <Author AffiliationIDS="A1">
                        <AuthorName DisplayOrder="Western">
                           <GivenName>Tomohisa</GivenName>
                           <FamilyName>Furuta</FamilyName>
                        </AuthorName>
                     </Author>
                     <Author AffiliationIDS="A1">
                        <AuthorName DisplayOrder="Western">
                           <GivenName>Takashi</GivenName>
                           <FamilyName>Ohmoto</FamilyName>
                        </AuthorName>
                     </Author>
                     <Affiliation ID="A1">
                        <OrgName>Department of Neurological Surgery, Okayama University Medical School, 2-5-1 Shikata-cho, Okayama 700-8558, Japan</OrgName>
                        <OrgAddress>
                           <Street/>
                           <Postbox/>
                           <Postcode/>
                           <City/>
                           <State/>
                        </OrgAddress>
                     </Affiliation>
                  </AuthorGroup>
                  <Abstract ID="Abs1" Language="En">
                     <Heading>Abstract.</Heading>
                     <Para> Cyclin E and p27<Superscript>Kip1</Superscript> are co-regulators of the G1-to S-phase transition and closely related to tumor behavior. The purpose of this study was to examine expression of cyclin E and p27<Superscript>Kip1</Superscript> in astrocytomas and to evaluate the relationships between expression of these cell-cycle regulators and prognosis of patients with astrocytoma. Tissue samples from 130 astrocytomas (WHO grade 1<Emphasis Type="Italic"> n</Emphasis>=5, grade 2<Emphasis Type="Italic"> n</Emphasis>=23, grade 3<Emphasis Type="Italic"> n</Emphasis>=64, grade 4<Emphasis Type="Italic"> n</Emphasis>=38) were examined immunohistochemically for cyclin E and p27<Superscript>Kip1</Superscript> expression. Patient charts were reviewed for clinical presentation, and survival was followed. The cyclin E labeling index (LI) tended to increase with tumor grade (Kruskal-Wallis,<Emphasis Type="Italic"> P</Emphasis>=0.0104). For patients with primary astrocytomas, the 50% survival times for the low cyclin E LI (&lt;5%) group and the high cyclin E LI(≥5%) group were 53.7 months and 19.8 months. In combined analysis of cyclin E and p27<Superscript>Kip1</Superscript> expression, the low cyclin E/high p27<Superscript>Kip1</Superscript> LI (≥50%) group had the best survival (50% survival time: 103.2 months), the low cyclin E/low p27<Superscript>Kip1</Superscript> LI (≥50%) and the high cyclin E/high p27<Superscript>Kip1</Superscript> LI groups moderate survival (24.1 and 27.5 months), and the high cyclin E/low p27<Superscript>Kip1</Superscript> LI group the worst survival (13.1 months). Multivariate analysis identified the combined factor, high cyclin E/low p27<Superscript>Kip1</Superscript>, as a novel independent prognostic factor for survival time (<Emphasis Type="Italic">P</Emphasis>=0.0037, relative risk=2.4). This study suggested that combined analysis of cyclin E and p27<Superscript>Kip1</Superscript> expression was considered to be potentially useful in predicting the prognosis of patients with astrocytoma.</Para>
                  </Abstract>
                  <KeywordGroup Language="En">
                     <Keyword>Astrocytoma Cyclin E p27Kip1 Immunohistochemistry Prognosis</Keyword>
                  </KeywordGroup>
                  <ArticleNote Type="Misc">
                     <SimplePara>Electronic Publication</SimplePara>
                  </ArticleNote>
               </ArticleHeader>
               <BodyRef FileRef="BodyRef/PDF/401_2001_Article_261.pdf" TargetType="PDF"/>
            </Article>
         </Issue>
      </Volume>
   </Journal>
</Publisher>